Biocon Limited started FY27 on a positive note, delivering 10% year-on-year growth in revenue from operations despite mixed performance across its business segments. The company’s Biosimilars business continued to be the primary growth engine, while the Generics division showed significant improvement in profitability. However, the Services business faced temporary headwinds due to lower customer demand and foreign exchange losses.

Management remains optimistic that growth momentum will accelerate during the second half of FY27, supported by new product launches, expanded manufacturing capacity, and increasing global market opportunities.

Q1 FY27 Financial Highlights

Biocon reported Revenue from Operations of ₹4,336 crore, representing 10% year-on-year growth.

Key financial highlights include:

• Revenue from Operations: ₹4,336 crore (+10% YoY)
• Total Revenue: ₹4,391 crore
• EBITDA: ₹902 crore
• EBITDA Margin: 21%
• Profit Before Tax (before exceptional items): ₹141 crore
• Reported Net Profit: ₹141 crore, up 355% YoY
• R&D investment remained strong at ₹240 crore.

Although quarterly revenue declined slightly compared to Q4 FY26, the company maintained healthy profitability while continuing to invest in research and future product development.

Biosimilars Continue to Lead Growth

The Biosimilars segment remained Biocon’s strongest performer during the quarter.

Key Highlights

• Revenue increased 16% YoY to ₹2,855 crore
• EBITDA rose 10% YoY
• EBITDA Margin stood at 25%
• R&D spending remained at 7% of revenue

Growth was primarily driven by the North American market, where Biocon continues to expand its commercial presence and benefit from recent product launches.

Management expects Biosimilars growth to strengthen further during the second half of FY27 as recently launched products gain market share.

Another important milestone during the quarter was the EMA approval for the second insulin drug product line in Malaysia, effectively doubling manufacturing capacity for future growth.

Recent Global Product Launches Strengthen Portfolio

Biocon continues to expand its global biosimilars portfolio through new product launches across major markets.

North America

Recent commercial launches include:

• Yesafili (biosimilar aflibercept)
• Bosaya (biosimilar denosumab)
• Aukelso (biosimilar denosumab)
• Generic Liraglutide

The company also strengthened its regional supply network through local manufacturing capabilities and strategic partnerships.

Europe

Biocon now offers:

• 11 Biosimilars
• 8 Generic medicines

Recent launches include Evfraxy (biosimilar denosumab) and Abevmy (biosimilar bevacizumab) across select European markets.

Emerging Markets

Growth initiatives include:

• Launch of Yesafili in Malaysia
• Continued leadership in bevacizumab in Brazil
• Expanded commercial partnerships
• Technology transfer initiatives.

Generics Business Shows Improving Profitability

Biocon’s Generics segment delivered encouraging results despite a slight sequential decline in revenue.

Financial Highlights

• Revenue: ₹760 crore
• Year-on-Year Growth: 21%
• EBITDA Margin improved to 7%
• R&D intensity reduced to 6% of revenue

The major growth driver during the quarter was Generic Liraglutide, which performed well across multiple markets, including the United States.

Management highlighted that operating leverage and cost efficiency initiatives have started improving profitability. Investments in peptides, fermentation, and manufacturing infrastructure are expected to support additional margin expansion as production volumes increase.

Services Business Faces Temporary Challenges

The Services segment experienced a weaker quarter.

Revenue declined to ₹736 crore, while EBITDA margins moderated because of:

• Lower offtake from a major biologics customer
• Foreign exchange hedge losses

Despite these challenges, Biocon continued investing in capability building through strategic collaborations and digital transformation initiatives.

The company expects FY27 to be a transition year for this business, with stronger performance anticipated in the second half and sustainable growth targeted from FY28 onward.

Continued Investment in Innovation

Innovation remains central to Biocon’s long-term strategy.

During the quarter, the company continued investing in:

• Research & Development
• Manufacturing expansion
• AI-enabled drug discovery platforms
• Clinical development capabilities
• Strategic research collaborations

These investments are intended to strengthen the company’s future product pipeline and enhance long-term competitiveness.

Management Outlook for FY27

Management remains optimistic about the remainder of FY27.

The company expects:

• Stronger performance during the second half of FY27
• Continued Biosimilars-led growth
• Benefits from recent product launches
• Improved manufacturing utilization
• Better operating margins
• Higher free cash flow generation
• Improved Return on Capital Employed (RoCE)

Biocon also emphasized its focus on translating revenue growth into stronger shareholder returns through improved profitability and disciplined capital allocation.

Key Investment Positives

Several long-term factors continue to support Biocon’s growth story:

• Strong Biosimilars franchise with global presence
• Growing product portfolio across North America, Europe, and emerging markets
• Improving Generics profitability
• Robust research and development pipeline
• Expanded manufacturing capacity
• Integrated biotechnology platform
• Global commercial capabilities
• Focus on improving margins and cash generation.

Risks to Watch

Investors should monitor the following factors:

• Recovery in the Services business
• Regulatory approvals across key markets
• Product launch execution
• Foreign exchange fluctuations
• Pricing pressure in global pharmaceutical markets
• Commercial ramp-up of newly launched products

These factors will play an important role in determining Biocon’s earnings trajectory over the coming quarters.